Physician profile
Joseph Strauch
NPI 1306964309
$4,702.93
in general payments reported to CMS, 2019-2025
27 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $473 · 2021: $531 · 2022: $335 · 2023: $916 · 2024: $1,096 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.88 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $1,421.68 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $688.44 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $407.90 | 2020-2025 | |
| Dermavant Sciences, INC. | $319.46 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $300.25 | 2019-2024 | Cabtreo, Jublia, Arazlo |
| Sun Pharmaceutical Industries INC. | $294.57 | 2019-2025 | Winlevi, Blu-U, Odomzo |
| Pfizer INC. | $254.04 | 2019-2025 | |
| Amgen INC. | $215.09 | 2019-2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $151.84 | 2019-2022 | |
| Janssen Biotech, INC. | $106.29 | 2021-2024 | Tremfya |
| Abbvie INC. | $88.38 | 2023-2024 | Rinvoq |
| Genzyme Corporation | $63.30 | 2021-2023 | |
| Arcutis Biotherapeutics, INC. | $60.34 | 2023-2024 | Zoryve |
| Sebela Pharmaceuticals INC. | $57.42 | 2019-2020 | |
| Epi Health, LLC | $44.66 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $42.75 | 2022-2023 | Taltz, Olumiant |
| Incyte Corporation | $27.20 | 2023-2025 | Opzelura |
| Taro Pharmaceuticals USA, INC. | $21.04 | 2019 | |
| Organon LLC | $20.56 | 2025 | Vtama |
| Ucb, INC. | $16.61 | 2023 | Cimzia |
| Regeneron Healthcare Solutions, INC. | $16.20 | 2025 | Libtayo |
| Galderma Laboratories, L.P. | $15.64 | 2024 | Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.68 | 2024 | Spevigo |
| Lnhc, INC | $14.62 | 2025 | Zelsuvmi |
| Botanix Sb INC | $14.37 | 2025 | Sofdra |
| Merck Sharp & Dohme LLC | $13.75 | 2019 | |
| Biofrontera INC. | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Strauch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.